Hodgkin lymphoma (HL), formerly called Hodgkin's disease, is a rare monoclonal lymphoid neoplasm with high cure rates. Biological and clinical studies have divided this disease entity into 2 distinct categories: classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL). These 2 disease entities show differences in clinical picture and pathology. Classical Hodgkin lymphoma accounts for approximately 95% of all HL, and it is further subdivided into 4 subgroups: nodular sclerosis (NSHL), lymphocyte-rich (LRHL), mixed cellularity (MCHL), and lymphocyte-depleted (LDHL). Four features characterize Hodgkin lymphomas. They commonly arise in the cervical lymph nodes; the disease is more common in young adults; there are scattered large mononuclear Hodgkin and multinucleated cells (Reed-Sternberg) intermixed in a background of a mixture of non-neoplastic inflammatory cells; finally, T lymphocytes are often observed surrounding the characteristic neoplastic cells. Hodgkin lymphoma has an excellent overall prognosis with approximately 80% cure rate.
The exact etiology of Hodgkin lymphoma is unknown. However, there is increased risk of Hodgkin lymphoma in Epstein-Barr (EBV) infection, autoimmune diseases, and immunosuppression. There is also evidence of familial predisposition in Hodgkin lymphoma. EBV has been found to be more common in the mixed cellularity, and lymphocyte depleted subtypes of Hodgkin lymphoma. Loss of immune surveillance has been proposed as the possible disease etiology in EBV-positive disease. No other virus has been found to play a major contributing role in disease pathogenesis. Immunosuppression secondary to a solid organ or hematopoietic cell transplantation, therapy with immunosuppressive drugs, and human immunodeficiency (HIV) infection have all a higher risk of developing Hodgkin lymphoma. HIV patients commonly present with a more advanced stage, unusual lymph nodes sites and a poor prognosis. Studies found that there is a ten-fold increase of developing HL in same-sex siblings of patients with Hodgkin lymphoma suggesting a gene-environment interaction role in Hodgkin lymphoma predisposition.
Hodgkin lymphoma is a rare malignancy with an estimated incidence rate of 2.6 cases per 100,000 people in the United States. The disease represents 11% of all lymphomas seen in the United States. It has a bimodal distribution where most of the affected patients are between ages 20 to 40 years, and there is another peak from age 55 years and older. It affects males more than females especially in the pediatric population where 85% of cases occur in boys. Nodular sclerosis Hodgkin lymphoma is more common in young adults whereas mixed cellularity Hodgkin lymphoma tends to affect older adults. The incidence of classical Hodgkin lymphoma subtypes is as follows: nodular sclerosis classical Hodgkin lymphoma (70%), mixed cellularity classical HL (25%), lymphocyte-rich classical Hodgkin lymphoma (5%), and lymphocyte-depleted classical HL (less than 1%). NLPL represents approximately 5% of Hodgkin lymphoma in general.
Hodgkin lymphoma has unique neoplastic cells in both the classical and NLP-HL types. Reed-Sternberg (RS) cell is a neoplastic, large multinucleated cell with 2 mirror-image nuclei (owl eyes) within a reactive cellular background. The RS cell is pathognomonic for classical HL. RS cells are derived from germinal center B cells with mutations of IgH-variable region segment. The RS secrete cytokines to recruit reactive cells that include IL-5 and transforming growth factor-beta (TGF-beta). The RS cell is usually aneuploid with no consistent cytogenetic abnormality. Clonal Ig gene rearrangements have been found in the majority of isolated RS cells. Immunohistochemistry stains for RS cells are positive for CD30, CD15, but typically negative for CD20 and CD45 that are positive only in neoplastic NLP-HL cells. In addition to CD15 and CD30, RS cells are usually positive for PAX5, CD25, HLA-DR, ICAM-1, Fascin, CD95 (apo-1/fas), TRAF1, CD40, and CD86. There are RS cells variants that include the Hodgkin cell, mummified cells, and lacunar cells. Hodgkin cells are mononuclear RS-cell variants. Mummified cells show condensed cytoplasm and pyknotic reddish nuclei with smudgy chromatin. Lacunar cells have multilobulated nuclei, small nucleoli, and abundant, pale cytoplasm that often retracts during tissue fixation and sectioning, leaving the nucleus in what appears to be empty space (lacune-like space). On the other hand, NLP-HL lacks the typical RS cells but has lymphocytic and histiocytic cells, which are characterized by larger cells with folded multilobulated nuclei (also known as “popcorn cells” or LP cells). The LP cells show a nucleus with multiple nucleoli that are basophilic and smaller than those seen in RS cells. LP cells show clonally rearranged immunoglobulin genes that are only detected in isolated single LP cells. The LP cells are usually positive for C020, CD45, EMA, CD79a, CD75, BCL6, BOB.1, OCT2, and J chain.
Morphology is used to determine Hodgkin lymphoma variants and NLP-HL. Nodular sclerosis HL shows a partially nodular growth pattern, with fibrous bands and inflammatory background. RS cells are rare. However, lacunar cells are more common. Mixed cellularity HL shows a diffuse or vaguely nodular growth pattern without sclerosis bands in an inflammatory background. Fine interstitial fibrosis may be present, and classical diagnostic Reed Sternberg cells are common. Lymphocyte-rich HL commonly shows a nodular growth pattern in an inflammatory background that consists predominantly of lymphocytes, with rare or no eosinophils or neutrophils. RS cells and mononuclear Hodgkin cells are usually present. Lymphocyte depleted HL has a diffuse hypocellular growth pattern with increased areas of fibrosis, necrosis, and uncommon inflammatory cells. RS cells are usually present. NLPHL is characterized by overall nodular architecture with LP cells in a background of small B lymphocytes, follicular dendritic cells, and follicular T lymphocytes. In conclusion, morphology and immunophenotype of both the neoplastic cells and the background infiltrate are crucial in diagnosing HL and its different subtypes. In summary, correct morphological and immunophenotypic assessment in HL is important for the correct diagnosis of the disease entity.
Hodgkin lymphoma patients frequently present with painless supra-diaphragmatic lymphadenopathy (one to two lymph node areas), B symptoms including unexplained profound weight loss, high fevers, and drenching night sweats. B symptoms are evident in up to 30% of patients and are generally more common in stage 3 to 4 of the disease, mixed cellularity, and lymphocyte depleted HL subtypes. Pain in lymph nodes may occur with alcohol consumption (paraneoplastic symptom). Chronic pruritus is another disease symptom that may be encountered. If mediastinal nodes enlargement is significant, the mass effect can produce chest pain and shortness of breath. If the patient has an extra-nodal disease, which is less common, related clinical manifestations may occur.
Each subtype of Hodgkin lymphoma has distinct clinical features. Nodular sclerosis subtype affects young adults and presents with early disease stage; while mixed cellularity HL is prevalent in both children and elderly patients and commonly presents with advanced disease stage. Lymphocyte depletion HL presents with the extensive extranodal disease, affects elderly patients and is associated with AIDS infection. Lymphocyte-rich classical HL presents with localized painless peripheral lymphadenopathy similar to NLP-HL. NLP-HL is a distinct, unique clinicopathological entity that is distinct from classical HL. It presents in males with localized painless peripheral lymphadenopathy in the neck that often spares the mediastinum. NLP-HL shows a more indolent course with a tendency for late relapses.
Definitive diagnosis for Hodgkin lymphoma is through biopsy from a lymph node or suspected organ. It is important to note that fine-needle aspiration or core-needle biopsy frequently show non-specific findings because of the low ratio of malignant cells and loss of architectural information. So excisional biopsy should be pursued if suspicion of Hodgkin lymphoma is high. An RS cell or LP cell need to be identified within the biopsy specimen to establish a definitive diagnosis. Further workup is essential to determine the stage, which guides treatment and provide prognostic information. Laboratory tests include complete blood count (CBC), complete metabolic panel (CMP), ESR, HBV, HBC, and HIV. Chest x-ray, CT chest/abdomen/pelvis, and PET/CT scans can help with staging. PET-CT scanning has now become a standard test for assessment of treatment response in HL and most lymphomas. Overall, a comprehensive workup is essential for both diagnosis and staging of Hodgkin lymphoma.
Treatment of Hodgkin lymphoma largely depends on the histologic characteristics, the stage of the disease, and the presence or absence of prognostic factors. The goal of treatment for patients with Hodgkin lymphoma is to cure the disease with control of short and long-term complications. There are several different staging systems for Hodgkin lymphoma, and the Cotswolds modified Ann Arbor classification is commonly used. The International Prognostic Factors Project on Advanced Hodgkin's lymphoma identified 7 variables for patients with advanced disease:
Risk stratification categorizes patients as low risk or high risk for recurrence. The response to therapy is determined by PET scan and is used to optimize therapy. Initial treatment of Hodgkin lymphoma depends on the subgroup treatment. There are 3 treatment subgroups: patients with the early-stage disease with favorable prognostic factors, patients with the limited-stage disease who have unfavorable prognostic factors, and those with advanced-stage disease. Patients who are in early-stage (stage I to IIA) with favorable prognostic features are treated with short duration of chemotherapy, typically 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) followed by restricted involved-field radiation therapy (IFRT). Patients who are in limited-stage disease but with unfavorable features such as bulky mediastinal disease, elevated ESR and extra-nodal extension are treated with a longer course of chemotherapy (4 to 6 cycles) followed by a higher dose of IFRT. Patients with advanced-stage (stage IIB to IV) are risk stratified by a different scoring system, the International Prognostic Score (IPS). Depending on IPS, different chemotherapy regimen (for example, escalated BEACOPP and Stanford V) can be used, but the standard of care is ABVD for most patients. Radiation, in general, is not beneficial in these patients. Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving an initial complete remission. High-dose chemotherapy followed by an autologous stem cell transplant is the standard of care for the majority of patients who are refractory or relapse post-initial therapy. For patients who fail autologous transplantation treatment options include: brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplantation or clinical trials. Future directions in the management of Hodgkin lymphoma will include the incorporation of frontline therapeutics that have shown efficacy in refractory/relapses disease setting as well as other possible novel therapeutics.
Treatment of Hodgkin lymphoma is based on clinical staging of the disease. The modified Ann Arbor staging system is the most common staging system. The staging system for Hodgkin lymphoma is based on the location of lymphadenopathy, the number, and size of lymph node, and whether the extranodal lymph node involvement is shown systemic. Commonly used staging system divides the disease into 4 stages:
Prognosis depends on several prognostic factors including disease stage. Disease stage is currently only one factor in the prognostic indices used for pretreatment risk stratification and assessment. The 5-year overall survival (OS) in stage 1 or 2a is approximately 90%; on the other hand, stage 4 disease has a 5-year OS of approximately 60%.
The management of Hodgkin lymphoma is primarily by the oncologists. However, the patient may first present to the primary care provider or nurse practitioner with symptoms suggestive of the lymphoma. The key is prompt referral so that therapy can be initiated. Treatment of Hodgkin lymphoma largely depends on the histologic characteristics, the stage of the disease, and the presence or absence of prognostic factors. The goal of treatment for patients with Hodgkin lymphoma is to cure the disease with control of short and long-term complications.
Prognosis depends on several prognostic factors including disease stage. Disease stage is currently only one factor in the prognostic indices used for pretreatment risk stratification and assessment. The 5-year overall survival (OS) in stage 1 or 2a is approximately 90%; on the other hand, stage 4 disease has a 5-year OS of approximately 60%.(Level V)
|||Lees C,Keane C,Gandhi MK,Gunawardana J, Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. British journal of haematology. 2019 Feb 10; [PubMed PMID: 30740662]|
|||Amraee A,Evazi MR,Shakeri M,Roozbeh N,Ghazanfarpour M,Ghorbani M,Ansari J,Darvish L, Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study. Clinical [PubMed PMID: 30739242]|
|||Metzger ML,Mauz-Körholz C, Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. British journal of haematology. 2019 Feb 6; [PubMed PMID: 30729493]|
|||Childhood Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version 2002; [PubMed PMID: 26389170]|
|||Milgrom SA,Elhalawani H,Lee J,Wang Q,Mohamed ASR,Dabaja BS,Pinnix CC,Gunther JR,Court L,Rao A,Fuller CD,Akhtari M,Aristophanous M,Mawlawi O,Chuang HH,Sulman EP,Lee HJ,Hagemeister FB,Oki Y,Fanale M,Smith GL, A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Scientific reports. 2019 Feb 4; [PubMed PMID: 30718585]|
|||Lyapichev KA,You MJ, Unusual presentation of classic Hodgkin lymphoma. Blood. 2019 Jan 31; [PubMed PMID: 30705049]|
|||Justiz Vaillant AA,Stang CM, Lymphoproliferative Disorders 2018 Jan; [PubMed PMID: 30725847]|
|||Gaut D,Schiller GJ, Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature. International journal of hematology. 2019 Jan 22; [PubMed PMID: 30671909]|
|||Cai Q,Fang Y,Young KH, Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment. Translational oncology. 2019 Mar; [PubMed PMID: 30616219]|
|||Hoppe RT,Advani RH,Ai WZ,Ambinder RF,Aoun P,Armand P,Bello CM,Benitez CM,Bierman PJ,Chen R,Dabaja B,Dean R,Forero A,Gordon LI,Hernandez-Ilizaliturri FJ,Hochberg EP,Huang J,Johnston PB,Kaminski MS,Kenkre VP,Khan N,Maddocks K,Maloney DG,Metzger M,Moore JO,Morgan D,Moskowitz CH,Mulroney C,Rabinovitch R,Seropian S,Tao R,Winter JN,Yahalom J,Burns JL,Ogba N, NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Mar; [PubMed PMID: 29523663]|
|||Gordon LI, Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 May; [PubMed PMID: 28515253]|
|||Klimm B,Goergen H,Fuchs M,von Tresckow B,Böll B,Meissner J,Glunz A,Diehl V,Eich HT,Engert A,Borchmann P, Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Dec; [PubMed PMID: 24148816]|
|||Hoppe RT,Advani RH,Ai WZ,Ambinder RF,Aoun P,Bello CM,Bierman PJ,Blum KA,Chen R,Dabaja B,Duron Y,Forero A,Gordon LI,Hernandez-Ilizaliturri FJ,Hochberg EP,Maloney DG,Mansur D,Mauch PM,Metzger M,Moore JO,Morgan D,Moskowitz CH,Poppe M,Pro B,Winter JN,Yahalom J,Sundar H, Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 May; [PubMed PMID: 22570290]|
|||Chihara D,Oki Y,Fanale MA,Westin JR,Nastoupil LJ,Neelapu S,Fayad L,Fowler NH,Cheah CY, Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Annals of hematology. 2019 Jan 8; [PubMed PMID: 30617643]|
|||Ramchandren R,Advani RH,Ansell SM,Bartlett NL,Chen R,Connors JM,Feldman T,Forero-Torres A,Friedberg JW,Gopal AK,Gordon LI,Kuruvilla J,Savage KJ,Younes A,Engley G,Manley TJ,Fenton K,Straus DJ, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 7; [PubMed PMID: 30617130]|